{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089437","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.427909+00:00","generated_at":"2026-06-11T18:51:18.187307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Liquidia Q2 net loss widens to $23.5M; YUTREPIA patent litigation advances, L606 license acquired","bullets":["Net loss $23.5M ($0.36/sh) vs $9.4M ($0.15/sh) in Q2 2022; revenue $4.8M, up from $3.9M.","CAFC affirmed '066 patent invalid/non-infringed; one patent ('793) on appeal to CAFC, briefing Q4 2023.","Filed amendment to add PH-ILD to YUTREPIA label; final approval gated by Tyvaso exclusivity ending March 31, 2024.","Licensed L606 from Pharmosa for $10M upfront; Phase 3 PH-ILD study planned in 2024 after FDA meeting.","Cash $88.2M as of June 30, 2023, vs $93.3M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089437","json":"https://secwatch.observer/filing/0001104659-23-089437.json","markdown":"https://secwatch.observer/filing/0001104659-23-089437.md","text":"https://secwatch.observer/filing/0001104659-23-089437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/0001104659-23-089437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/tm2323188d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:51:18.187307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b199377cb32448cb4cfba5d9d04a13440a99f9c","claim":"Liquidia Corp reported second quarter ended June 30, 2023 results: revenue $4.8 million, net income $23.5 million, EPS $0.36 per basic and diluted share.","evidence_excerpt":"of PH-LD patients with L606. Second Quarter 2023 Financial Results Cash totaled $88.2 million as of June 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $4.8 million for the three months ended June 30, 2023, compared to $3.9 million for the three months ended June 30, 2022. Revenue related primarily to the promotion agreement between Liquidia","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/0001104659-23-089437-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$4.8 million"},{"label":"Net income","value":"$23.5 million"},{"label":"EPS","value":"$0.36 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}